IMVT

Immunovant, Inc.

Investor Moves

NameValueActionChangePriceLast Price
Steven CohenPoint72
$-50.8M
ExitQ1 2026
$51M
--
$38.96
Ken GriffinCitadel Advisors
$5M217.3k shares
TrimQ1 2026
$2M
$24.84
$38.96
Paul Tudor Jones IITudor Investment
$-2.2M
ExitQ1 2026
$2M
--
$38.96
Ken GriffinCitadel Advisors
$-6.8M
TrimQ4 2025
$7M
--
$38.96
Steven CohenPoint72
$-4.6M
TrimQ4 2025
$5M
--
$38.96
Ken GriffinCitadel Advisors
$6.9M
AddQ3 2025
$7M
--
$38.96

Insider Trades

NameValueActionPriceLast Price
Fromkin Andrew J.Director
$7M210.5k shares
SellMay 28, 2026
$33.56
$38.96
Fromkin Andrew J.Director
$375k11.5k shares
SellMay 28, 2026
$32.64
$38.96
Gloria MelanieChief Operating Officer
$56k1.7k shares
SellMay 20, 2026
$32.95
$38.96
Gloria MelanieChief Operating Officer
$38k1.2k shares
SellMay 20, 2026
$32.15
$38.96
Gloria MelanieChief Operating Officer
$7.6k249 shares
SellMay 20, 2026
$30.41
$38.96
Pande AtulDirector
$192k6k shares
SellMay 20, 2026
$32.00
$38.96

News

zacks.comImmunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?zacks.comJun 19zacks.comImmunovant Stock Gains 12.4% in a Month: What's Driving It?zacks.comJun 12seekingalpha.comImmunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potentialseekingalpha.comMay 25seekingalpha.comRoivant: Immunovant's Rheumatoid Arthritis Win Validates The Buyseekingalpha.comMay 21benzinga.comThese Analysts Increase Their Forecasts On Immunovant After Q4 Resultsbenzinga.comMay 21